Karo Pharma AB (Karo Pharma AB) EV-to-EBITDA : 100.66 (As of Jun. 13, 2024)

Karo Pharma AB EV-to-EBITDA Chart

Karo Pharma AB Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBITDA		Get a 7-Day Free Trial					34.30	13.11	26.75	22.90	24.92

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
EV-to-EBITDA	Get a 7-Day Free Trial															61.40	89.02	69.67	24.92	610.08

Competitive Comparison of Karo Pharma AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karo Pharma AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's EV-to-EBITDA falls into.

Karo Pharma AB EV-to-EBITDA Calculation

Karo Pharma AB's EV-to-EBITDA for today is calculated as:

Karo Pharma AB's current Enterprise Value is $2,341.2 Mil.
Karo Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karo Pharma AB  (OTCPK:KARBF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Karo Pharma AB's PE Ratio for today is calculated as:

Karo Pharma AB's share price for today is $5.25.
Karo Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Karo Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description